Brain

ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301

Safety, pharmacokinetics and target engagement data from first-in-human Phase 1 clinical trial in healthy volunteers will potentially enable rapid advancement…

1 year ago

Borvo Medical Announces U.S. FDA 510(k) Clearance for Innovative Surgical Device, Offering a Minimally Invasive Option for Surgical Brain Treatment

Borvo EVAC™ System Provides Advanced Approach for the Growing Number of PatientsRequiring Subdural Hematoma (SDH) Drainage Driven by Factors Such…

1 year ago

Diagonal Therapeutics to Present at the Cure HHT’s 15th International Scientific Conference

Diagonal is advancing its lead program to treat the underlying cause of hereditary hemorrhagic telangiectasia (HHT)WATERTOWN, Mass., Oct. 08, 2024…

1 year ago

IRLAB Receives Milestone Payment of USD 2.5 million in Conjunction with First Dosing in a Phase I Study with IRL757 in Healthy Older Adults

GOTHENBURG, SWEDEN / ACCESSWIRE / October 8, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company…

1 year ago

Route 92 Medical Files Patent Infringement Suit Against Q’Apel Medical

SAN MATEO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated…

1 year ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Strategic financing by an affiliate of CK Life Sciences Int’l., (Holdings) Inc., results in working capital of approximately $23 million…

1 year ago

Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries

ISTANBUL and LONDON, and BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the…

1 year ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson’s Disease Models GT-02287 Improves Mitochondrial Function and Provides Neuroprotective…

1 year ago

Neurotech is Changing the Way We Treat Disease and Understand the Brain; Are Our Medical and Legal Institutions Ready?

The Dana Foundation Launches Neurotech Justice Accelerator at Mass General Brigham (NJAM) to Unite Science and Society and Mitigate Medical,…

1 year ago